hVIVO signs new contracts with global biopharmaceutical firm
hVIVO has signed new contracts with a leading global biopharmaceutical company ▪ Contracted for two respiratory syncytial virus (RSV) human challenge studies ▪ Studies projected to deliver a total of c.£9m in revenue from Q4’18 through to end of 2019 ▪...
Read More
Queen Mary joins London cancer research powerhouse
Queen Mary joins London cancer research powerhouse The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today. The new Cancer...
Read MorehVIVO Landmark Asthma Stratification Initiative Underway
hVIVO plc (AIM: HVO), the pioneer of human disease models, is delighted to announce that the Company’s landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus (HRV) at hVIVO’s London based...
Read More
BioWednesday London: Immuno-Oncology Investment Forum
Immuno-Oncology Investment Forum Immuno-Oncology (IO) has been one of, if not the, hottest area in biopharma over recent years. High profile financings, approvals and challenges have emerged and competition for new innovative programmes is fierce. To...
Read More
Dementia Investment Forum
Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Supported by: Hume Brophy Date: 14th April Time: 14.00 – 19.30 Programme (subject to change) 14.00 Registration and refreshments 14.30 Welcome 14.45 Session 1: Investing in...
Read More
Retroscreen Virology Changes its Name to hVIVO
Retroscreen Virology is proud to announce corporate name change to hVIVO to reflect pioneering efforts in human disease models. Revolutionising drug development through human studies Retroscreen Virology, a leading life sciences human disease model...
Read More
What does London’s Life Sciences Sector Want From the Next Mayor?
What does London’s Life Sciences Sector want from the next Mayor? The first London Mayor, Ken Livingstone, used the London Development Agency as a delivery vehicle to create “BioLondon” as a brand and activity to promote London’s strengths and...
Read More
Batteries and Spyglasses Not Included
Graphene has been hailed as a new wonder material, yet since its discovery at Manchester University in 2004 the UK accounts for less than 1% of total graphene patents filed worldwide. To compete on the international stage, we need a more robust...
Read More
ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer
LAUSANNE, Switzerland & LONDON--(BUSINESS WIRE)--ADC Therapeutics Sarl (the Company or ADCT), the oncology research and development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced the appointment of Dr....
Read More
Science & Innovation Needs to be Part of a Broader Infrastructure Strategy
Dr. Ramsay Richmond is Executive Manager at the QMB Innovation Centre in Whitechapel. He has spent over 25 years in the European life sciences industry covering research, consultancy and business development. This article gives the views of the author...
Read More
Subscribe to
our Newsletter
More about
our Facilities
